

Medical Products Agency

CERTIFICATE NUMBER: 5.9.1-2022-074434

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER

Part 1

Issued following an inspection in accordance with : Art. 63 of Regulation (EU) 536/2014

The competent authority of Sweden confirms the following:

The manufacturer: Cellcolabs AB

Site address: Retzius Vag 8, Solna, 171 65, Sweden

OMS Organisation Id. / OMS Location Id.: ORG-100044682 / LOC-100073847

Has been inspected under the national inspection programme in connection with manufacturing authorisation no. 5.9.1-2022-074434 in accordance with Art. 61 of Regulation (EU) No 536/2014.

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on **2022-12-08**, it is considered that it complies with:

• The principles and guidelines of Good Manufacturing Practice laid down in Directive (EU) 2017/1572 and Commission Delegated Regulation (EU) 2017/1569³

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.



Online EudraGMDP, Ref key: 158052

Issuance Date 2023-02-16

Signatory: Bengt Berglund

Page 1 of 2

Postadress/Postal address: P.O. Box 26, SE-751 03 Uppsala, SWEDEN Besöksadress/Visiting address: Dag Hammarskjölds väg 42, Uppsala Telefon/Phone: +46 (0)18 17 46 00 Fax: +46 (0)18 54 85 66 Internet: www.lakemedelsverket.se E-mail: registrator@lakemedelsverket.se

¹The certificate referred to in paragraph Art. 15 of Directive 2001/20/EC, shall also be required for imports coming from third countries into a Member State.

²Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP database.

³These requirements fulfil the GMP recommendations of WHO.



Part 2

1 MA	NUFACTURING OPERATIONS
1.1	Sterile products
	1.1.1 Aseptically prepared (processing operations for the following dosage forms)
	1.1.1.4 Small volume liquids
	1.1.3 Batch certification
1.3	Biological medicinal products (list of product types)
	1.3.1 Biological medicinal products (list of product types)
	1.3.1.5 Biotechnology products
	1.3.2 Batch Certification (list of product types)
	1.3.2.5 Biotechnology products
1.5	Packaging
	1.5.2 Secondary packaging
1.6	Quality control testing
	1.6.4 Biological

Clarifying remarks (for public users)

Manufacturing of Human Investigational Medicinal Products. Manufacturing of ATMP from mesenchymal stem cells, cell suspension for injection/infusion for clinical trials.

2023-02-16



Name and signature of the authorised person of the Competent Authority of

Bengt Berglund

Bengt Berglund Tel:**+46 18 174600** Fax: **+46 18 548566**

Online EudraGMDP, Ref key: 158052

Issuance Date 2023-02-16

Signatory: Bengt Berglund

Page 2 of 2

Postadress/Postal address: P.O. Box 26, SE-751 03 Uppsala, SWEDEN Besöksadress/Visiting address: Dag Hammarskjölds väg 42, Uppsala Telefon/Phone: +46 (0)18 17 46 00 Fax: +46 (0)18 54 85 66 Internet: www.lakemedelsverket.se E-mail: registrator@lakemedelsverket.se